久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

產(chǎn)品分類(lèi)

BioSim Blosozumab ELISA Kit(KDJ48701)
  • 品牌:AntibodySystem
  • 產(chǎn)地:France
  • 型號:96 assays
  • 貨號:KDJ48701
  • 發(fā)布日期: 2022-07-25
  • 更新日期: 2024-07-23
產(chǎn)品詳請
產(chǎn)地 France
保存條件 2-8 ℃
品牌 AntibodySystem
貨號 KDJ48701
用途 For Research Use Only.
檢測方法 Elisa
保質(zhì)期 1 year
規格 96 assays
適應物種 Blosozumab
檢測限 0.156 ug /ml
數量 99999
標記物 Unconjugate
純度 95%%
樣本 Plasma, Serum
應用 Elisa
是否進(jìn)口


Catalog No.

KDJ48701

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Blosozumab

Alternative Names

LY2541546, CAS: 1132758-87-2

Background

Blosozumab is an IgG4-kappa type mouse monoclonal antibody optimized by humanization engineering with a molecular weight of 144.63 kDa. The monoclonal antibody was developed by Eli Lilly for the treatment of osteoporosis. Blosozumab can target and bind sclerostin (SOST) to play a biological role. In 2014, blosozumab was conducted a different doses of clinical trial about blosozumab was conducted to evaluate including drug safety, tolerance, pharmacokinetics and pharmacodynamics in postmenopausal women. The results showed that blosozumab had well tolerance and anabolic effect on bone, which could be used as a potential treatment for osteoporosis. In 2015, a randomized double-blind phase Ⅱ trial of blosozumab in postmenopausal women with low bone mineral density showed that blosozumab treatment resulted in a significant dose-dependent increase in bone mineral density, which further supports the conclusion that blosozumab is a potential anabolic therapy for osteoporosis. In September of the same year, women who had completed treatment were followed up to evaluate the effect of discontinuation of blosozumab. It was found that there were no adverse events related to the treatment one year after the cessation of treatment, and the anti-drug antibodies in the patients generally decreased.

Shipping

2-8 ℃

Note

For Research Use Only.


Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.




AntibodySystem由具有30多年蛋白抗體開(kāi)發(fā)經(jīng)驗的 創(chuàng )立于法國,專(zhuān)注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開(kāi)發(fā)了高效、高產(chǎn)的真核重組表達系統,利用該系統生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點(diǎn)蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區授權 ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準






盘山县| 当涂县| 新巴尔虎左旗| 临沭县| 龙岩市| 齐河县| 乌拉特后旗| 洞头县| 厦门市| 扬州市| 阿勒泰市| 阳城县| 梅河口市| 循化| 营口市| 延长县| 浦城县| 民权县| 临泽县| 边坝县| 伊春市| 黄平县| 右玉县| 岗巴县| 定西市| 上高县| 筠连县| 伊金霍洛旗| 全州县| 龙南县| 镇原县| 宁化县| 临潭县| 抚远县| 原阳县| 黑水县| 石首市| 武义县| 长顺县| 桐梓县| 藁城市|